Influenza, Human Clinical Trial
Official title:
Randomized, Double-blind, Comparative, Controlled Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old
Verified date | July 2022 |
Source | St. Petersburg Research Institute of Vaccines and Sera |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Comparative trial of tolerability, reactogenicity, safety and immunogenicity of the Flu-M vaccine as compared to the Vaxigrip® vaccine in terms of prevention of influenza in children aged 6 months to 9 years (at the time of the first vaccination).
Status | Completed |
Enrollment | 1066 |
Est. completion date | December 24, 2021 |
Est. primary completion date | October 29, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Months to 9 Years |
Eligibility | Inclusion Criteria: - For volunteers aged 3 to 9 years: - Healthy children of both sexes aged 3 to 9 years (3 years 0 months 0 days - 8 years 11 months 30 days); - The written and dated informed consent of one of the parents for participation in the trial; - For volunteers aged 6 to 35 months: - Healthy children of both genders aged 6 to 35 months, inclusive (6 months 0 days - 35 months 30 days); - The written and dated informed consent of one of the parents for participation in the trial; - The trial subject of the was born full-term, with the Apgar score of 7-10 points. - For all volunteers: Ability of a volunteer's parents to fulfill the requirements of the Protocol (i.e. to fill out the Patient Diary, come to visit with the volunteer). Exclusion Criteria: 1. History of influenza (including in mothers for children aged 6 to 35 months) or previous influenza vaccination during 6 months before the trial; 2. Positive result of the SARS-CoV-2 test; 3. Vaccination of the pregnant woman in the 2nd-3rd trimester (for the age group of 6 - 35 months) with an influenza vaccine; 4. Vaccination with any vaccine less than 30 days before participating in the trial or scheduled vaccination with any vaccine within 30 days after vaccination with the trial vaccines; 5. A serious post-vaccination reaction (temperature above 40 °C, hyperemia or edema more than 8 cm in diameter at the injection site) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination), encephalopathy; 6. Allergic reactions to vaccine components or any previous vaccination; 7. History of allergic reaction to chicken protein; 8. History of cancer, leukemia, tuberculosis, autoimmune diseases; 9. Carriage of HIV, syphilis, hepatitis B and C in the medical history, including by parents; 10. Children who received immunoglobulin products or transfusions of whole blood or its components less than 3 months before the start of the trial; 11. Long-term use (more than 14 days) of any immunomodulating medicines less than 3 months before the start of the trial; 12. Any confirmed or suspected immunosuppressive or immunodeficiency condition; 13. History of chronic diseases of the cardiovascular, bronchopulmonary, endocrine systems, blood in the acute stage (recovery less than 4 weeks before vaccination) or in the decompensation stage; 14. Children with hemophilia who may develop bleeding after intramuscular injection; 15. History of progressive neurological pathology, convulsive syndrome, afebrile convulsions; 16. History of acute infectious diseases (fever = 37.5°?): recovery less than 2 weeks before vaccination; 17. Participation in another clinical trial less than 3 months before the start of the trial; 18. History of mental illness of the child and the volunteer's parents; 19. The history of the volunteer's parent being registered with a tuberculosis dispensary and/or a narcological dispensary; 20. Maternal history of drug use or alcohol abuse during pregnancy and/or breastfeeding; 21. Pronounced congenital malformations in a child; 22. Suspected developmental delay in a child. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | LLC "Energiya zdorov'ya" | Saint Petersburg | |
Russian Federation | St. Petersburg State Budgetary Institution of Health Care "Children's City Polyclinic No. 45" of the Nevsky District | Saint Petersburg |
Lead Sponsor | Collaborator |
---|---|
St. Petersburg Research Institute of Vaccines and Sera |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline seroconversion level | Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay) The upper limit of bilateral 95 % CI for the difference between seroconversion levels (seroconversion level reference vaccine - the seroconversion level trial vaccine) should not exceed 10%.
Seroconversion = 40% |
Days 0 (screening), 28, 56, 180 after vaccination/revaccination | |
Secondary | Change from Baseline Geometric mean titer (GMT) of antibodies | Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay) The upper limit of bilateral 95% CI for the GMT ratio (GMTreference vaccine/GMTtrial vaccine) should not exceed 1.5 | Days 0 (screening), 28 after vaccination/revaccination | |
Secondary | Change from Baseline Seroconversion factor | Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay) Seroconversion factor = 2.5 | Days 0 (screening), 28, 56, 180 after vaccination/revaccination | |
Secondary | Change from Baseline Seroprotection rate | Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay) Seroprotection = 70% | Days 0 (screening), 28, 56, 180 after vaccination/revaccination | |
Secondary | Change from Baseline Seroconversion rate for each virus strain | Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay) | Days 0 (screening), 28, 56, 180 after vaccination/revaccination | |
Secondary | Incidence of immediate adverse events (allergic reactions) | Anaphylaxis, Quincke's edema, Urticaria. | 2 hours after vaccination/revaccination | |
Secondary | Incidence of local adverse events | Pain at the injection site at palpation, Hyperemia at the injection site, infiltrate at the injection site, Edema at the injection site, Pruritus at the injection site, Enlarged regional lymph nodes. | Day 1 (2 and 5-8 hours after vaccination/revaccination), days 2-180 | |
Secondary | Incidence of systemic adverse events | Headache, Cough, Sore throat, Nausea, Increased sweating, Arthralgia, Myalgia, Fever, Chills, Asthenia | Day 1 (2 and 5-8 hours after vaccination/revaccination), days 2-180 | |
Secondary | Incidence of severe adverse events during the trial | Day 1 (2 and 5-8 hours after vaccination/revaccination), days 2-180 | ||
Secondary | Number of participants with abnormal changes in physical examination data | Physical examination of volunteers includes an interview, discovery of complaints and symptoms, when required, palpation, auscultation, percussion; examination of skin, mucosa, eyes, oral cavity and pharynx, lungs/chest, heart/cardiovascular system, abdominal organs, nervous system, lymph nodes, musculoskeletal system. | Days 0 (screening), 3, 7, 28, 56 | |
Secondary | Number of participants with abnormal changes of neurological status | Days 0 (screening), 3, 7, 28, 56 | ||
Secondary | Number of participants with abnormal changes in vital signs - Blood pressure (BP) | BP measurements include the systolic and diastolic blood pressure. | Days 0 (screening), 3, 7, 28, 56 | |
Secondary | Number of participants with abnormal changes in vital signs - Heart rate (HR) | HR is measured using a phonendoscope at the apex of the heart during 1 minute. | Days 0 (screening), 3, 7, 28, 56 | |
Secondary | Number of participants with abnormal changes in vital signs - Respiratory rate (RR) | RR is counted with a hand placed on the child's chest or abdomen or by holding a stethoscope at the child's nose. The measurement is carried out during one minute. | Days 0 (screening), 3, 7, 28, 56 | |
Secondary | Number of participants with abnormal changes in vital signs - Body temperature | Measurement with a digital thermometer. | Day 0 (screening); 10 min before, 20 min and 2 hours after vaccination; days 3, 7, 28, 56 | |
Secondary | Number of participants with clinically significant abnormalities - Complete blood count (CBC) | Hemoglobin, hematocrit, erythrocytes, leukocytes, leukocytic formula, platelets, erythrocyte sedimentation rate (ESR). | Days 0 (screening), 3 | |
Secondary | Number of participants with clinically significant abnormalities - Biochemical blood test (BBT) | ALT, AST, LDH, alkaline phosphatase, total bilirubin, urea, glucose. | Days 0 (screening), 3 | |
Secondary | Number of participants with clinically significant abnormalities - Urinalysis | pH, specific density, protein, glucose, erythrocytes, leukocytes. | Days 0 (screening), 3 | |
Secondary | Number of participants with abnormal changes of total IgE | Days 0 (screening), 3, 56 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Completed |
NCT03275389 -
A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
|
Phase 1 | |
Completed |
NCT05981846 -
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
|
Phase 2 | |
Completed |
NCT05044195 -
A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age
|
Phase 3 | |
Completed |
NCT02914275 -
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
|
Phase 3 | |
Completed |
NCT04590066 -
Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy
|
N/A | |
Recruiting |
NCT03778203 -
Development of Childhood Anti-influenza Immunity
|
Phase 4 | |
Completed |
NCT04527614 -
Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection
|
N/A | |
Terminated |
NCT03658629 -
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
|
Phase 2 | |
Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
Withdrawn |
NCT02883972 -
Childhood Influenza Immunisation Invitation Trial in Schools
|
N/A | |
Completed |
NCT02867358 -
A Clinical Trial of KT07 Capsule in the U.S.A
|
Phase 2 | |
Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
Completed |
NCT02998996 -
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU
|
Phase 1/Phase 2 | |
Completed |
NCT02545543 -
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
|
Phase 3 | |
Completed |
NCT02243774 -
Mail Outreach To Increase Vaccination Acceptance Through Engagement
|
N/A | |
Completed |
NCT02621164 -
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents
|
Phase 3 | |
Completed |
NCT02212106 -
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
|
Phase 4 | |
Completed |
NCT02344134 -
Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects
|
Phase 3 |